Vaccines and Global Health: The Week in Review :: 28 September 2019

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_28 Sep 2019

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Creation of the Alliance Pasteur Mérieux International

Milestones :: Perspectives :: Research


Creation of the Alliance Pasteur Mérieux International
Two major French players in the fight against infectious diseases join forces to improve public health in vulnerable countries
September 24, 2019, Lyon (France)
The Institut Pasteur and the Mérieux Foundation announce the formation of an alliance to strengthen public health systems in limited resource settings and epidemic preparedness in the face of an ever-changing infectious disease threat. The agreement signed by Christian Vigouroux, Chairman of the Board of Directors of the Institut Pasteur, and Alain Mérieux, President of the Mérieux Foundation, accompanied by Stewart Cole, President of the Institut Pasteur and Bernard Sinou, Interim Director General of the Mérieux Foundation, brings together two major players in the fields of research and public health.

With a long experience in the field, working with the Institut Pasteur International Network and the Mérieux Foundation’s GABRIEL network, the two partners have already collaborated on close to a dozen international projects, demonstrating their complementary expertise. This agreement will strengthen synergies between their networks, bringing together over 50 centers on five continents.

As a platform recognized by public authorities and international organizations, the alliance will be poised to build projects, with public and private funding, to improve public health in the most vulnerable regions.

It will therefore help support the implementation of the Sustainable Development Goals (SDGs) for global health.

The alliance, known as the Alliance Pasteur Mérieux International, will be backed by a foundation, created by the two partners and placed under the aegis of the Institut Pasteur. This will make it possible to jointly manage projects and provide a main focal point for funders from the public and private sectors, from France and abroad.

“The Institut Pasteur embodies scientific excellence and a Pasteurian tradition that has brought French medicine to all parts of the world,” said Alain Mérieux, President of the Mérieux Foundation. “The Mérieux Foundation, moreover, brings a very strong understanding of the field and the power of its network of sentinel laboratories, created in partnership with local public health authorities.”

“The Institut Pasteur’s commitment to this alliance is based on its expertise in responding to health crises in terms of research, capacity building through training, and cooperation with local stakeholders, thus contributing to the improvement of surveillance and warning systems in the concerned countries,” declared Christian Vigouroux, Chairman of the Institut Pasteur Board of Directors.

Multilateral agencies launch a joint plan to boost global health goals

Milestones :: Perspectives :: Research


Multilateral agencies launch a joint plan to boost global health goals
Health, development and humanitarian agencies will collaborate for greater efficiency and more streamlined support to countries to deliver universal health coverage and achieve the health-related Sustainable Development Goals targets

New York | Joint news release | 24 September 2019 – Today at the United Nations General Assembly, 12 multilateral agencies launched a joint plan to better support countries over the next 10 years to accelerate progress towards the health-related Sustainable Development Goals (SDGs).


Developed over 18 months, Stronger Collaboration, Better Health: Global Action Plan for Healthy Lives and Well-being for All outlines how a dozen multilateral health, development and humanitarian agencies will collaborate to be more efficient and provide more streamlined support to countries to deliver universal health coverage and achieve the health-related SDG targets.

Healthy people are essential for sustainable development and for ending poverty, promoting peaceful and inclusive societies as well as protecting the environment. Over the last few decades, significant gains have been made in key areas of health, but the 2030 targets will not be met without redoubled efforts.

“The plan is called, ‘Stronger Collaboration, Better Health’ for a reason,” said Dr Tedros Adhanom Ghebreyesus, Director-General of WHO. “Although collaboration is the path, impact is the destination. The release of this plan is the beginning, not the end, of that path.”

Universal health coverage is key to meeting the health-related goals and addressing health inequities. If trends continue, up to 5 billion of the world’s population will not be covered by essential health services in 2030, as highlighted in the Universal Health Coverage: Global Monitoring Report, released last week by WHO. To leave no one behind, countries need to address health inequities. Improved collaboration and coordination can help countries tackle complex health challenges and bring innovative solutions.

Together, the 12 agencies contribute nearly one-third of all development assistance to health. Under the Global Action Plan, the agencies commit to strengthening their collaboration to:
:: Engage with countries better to identify priorities, plan and implement together;

:: Accelerate progress in countries through joint actions under 7 accelerator themes, which represent common challenges for many countries and where the agencies’ mandates, expertise and resources offer solutions, namely: 1) Primary health care 2) Sustainable health financing 3) Community and civil society engagement 4) Determinants of health 5) Innovative programming in fragile and vulnerable settings and for disease outbreak responses 6) Research and development, innovation and access, and 7) Data and digital health. They will also work together to advance gender equality and support the delivery of global public goods;

:: Align by harmonizing their operational and financial strategies and policies in support of countries to increase efficiency and reduce the burden on countries; and

:: Account, by reviewing progress and learning together to enhance shared accountability.

Governments are setting priorities, developing implementation plans and intensifying efforts to achieve the health-related SDG targets. Demand from countries for the Global Action Plan is growing. “Achieving the health-related SDG goals is key for Nepal. Strengthening primary health care and enhancing data utilization for evidence-based planning and decision-making are two accelerators that will help bring us closer to achieving the SDG goals,” said Deputy Prime Minister of Nepal, Mr Upendra Yadav.

Through the Global Action Plan, the agencies will help countries deliver on international commitments in addition to the SDGs, such as those made in Astana on primary health care and at the UN General Assembly High-level Meeting on Universal Health Coverage this week in New York.

Coordinated by WHO, the Global Action Plan for Healthy Lives and Well-being for All, is in response to a call from Germany, Ghana and Norway, with support from the United Nations Secretary-General, Antonio Guterres, for more effective collaboration and coordination among global health organizations to achieve the health-related SDGs.


The 12 signatory agencies to the plan are Gavi, The GFF, the Global Fund, UNAIDS, UNDP, UNFPA, UNICEF, UNITAID, UN Women, World Bank Group, WFP and WHO.

Countries must invest at least 1% more of GDP on primary health care to eliminate glaring coverage gaps – WHO

Milestones :: Perspectives :: Research


Countries must invest at least 1% more of GDP on primary health care to eliminate glaring coverage gaps – WHO
At current rates of progress up to 5 billion people will miss out on health care in 2030
22 September 2019 News release
Countries must increase spending on primary healthcare by at least 1% of their gross domestic product (GDP) if the world is to close glaring coverage gaps and meet health targets agreed in 2015, says a new report from the World Health Organization and partners on the eve of a UN General Assembly high-level meeting on Universal Health Coverage.

They must also intensify efforts to expand services countrywide.

The world will need to double health coverage between now and 2030, according to the Universal Health Coverage Monitoring Report. It warns that if current trends continue, up to 5 billion people will still be unable to access health care in 2030 – the deadline world leaders have set for achieving universal health coverage. Most of those people are poor and already disadvantaged.

Primary health care key to health for all
“If we are really serious about achieving universal health coverage and improving people’s lives, we must get serious about primary health care,” says Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “That means providing essential health services like immunization, antenatal care, healthy lifestyle advice as close to home as possible – and making sure people do not have to pay for this care out of their own pockets.”

Investing an additional USD200 billion a year on scaling up primary health care across low and middle-income countries would potentially save 60 million lives, increase average life expectancy by 3.7 years by 2030, and contribute significantly to socio-economic development. It would represent about 3% increase on the USD7.5 trillion already spent on health globally each year….

Using Data to Save Lives: The Rockefeller Foundation and Partners Launch $100 Million Precision Public Health Initiative

Milestones :: Perspectives :: Research


Using Data to Save Lives: The Rockefeller Foundation and Partners Launch $100 Million Precision Public Health Initiative
Initiative Aims to Prevent 6 Million Deaths by 2030
Brings Data Science and Machine Learning to Community Health Systems and Frontline Workers

NEW YORK, Sept. 25, 2019 /PRNewswire/ — The Rockefeller Foundation and leading global health partners announced today a $100 million Precision Public Health initiative to empower community health systems and frontline health workers with the latest data science innovations, including more accurate and precise decision-making tools based on large, integrated datasets, predictive analytics, artificial intelligence, and machine learning. The initiative aims to prevent 6 million deaths in 10 countries by 2030, by enabling frontline health workers with simple, inexpensive data analytic tools.

This initiative will address the reality that data science and new innovations are not reaching the people who need them most. The Precision Public Health initiative will leverage technologies that are transforming health in wealthy countries to dramatically reduce preventable maternal and child deaths. Partners and collaborators for this initiative include UNICEF; the World Health Organization; The Global Fund; the Global Financing Facility supported by The World Bank Group; and Gavi, the Vaccine Alliance.

“We have an unprecedented opportunity to leverage advances in data science and technology that have enriched the lives of society’s most privileged, and transform health for those left behind around the world,” said Dr. Rajiv J. Shah, President of The Rockefeller Foundation. “Working together, we can close the health inequity gap by driving innovation and investment to save millions of lives.”

The initiative will build upon a number of similar efforts on a smaller scale that have already shown encouraging results in applying data science to better deploy life-saving health tools. These include developing real-time risk maps to direct frontline health workers to areas of greatest need, and analyzing non-health data like climate patterns or social media trends to predict and better address health emergencies weeks in advance.

The Rockefeller Foundation-UNICEF Partnership
This initiative will begin in India and Uganda and expand to eight additional countries by 2030.  The work in India and Uganda will focus on reducing maternal and child mortality through a partnership with The Rockefeller Foundation and UNICEF. The integration and analysis of disparate data will enable decentralized decision-making and near real-time monitoring across the primary and community health systems to accelerate the impact of interventions on maternal and child health outcomes. Best practices and key learnings will be applied in additional countries through the regional UNICEF Eastern and Southern Africa Office to accelerate progress and scale.

“Data is a powerful tool that can help us make life-saving decisions and prevent epidemics before they happen,” said Ms. Henrietta Fore, Executive Director of UNICEF. “Timely, reliable, and disaggregated data, underpinned by a commitment to universal health coverage, can ensure that vulnerable women, children, and young people get the care they need at the right place and the right time.”…

UM School Of Medicine’s Center For Vaccine Development And Global Health Receives NIH Contract Of Up To More Than $200 Million For Influenza Research

Milestones :: Perspectives :: Research


UM School Of Medicine’s Center For Vaccine Development And Global Health Receives NIH Contract Of Up To More Than $200 Million For Influenza Research
Dr. Kathleen Neuzil to Lead Major Research Collaborative with Ultimate Goal of Protecting Millions Against Emerging Influenza Strains
BALTIMORE, Sept. 23, 2019 /PRNewswire/ — – Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.

This research contract is one of the largest ever awarded to UMSOM and includes an initial award of approximately $2.5 million to conduct clinical testing of influenza vaccines. Total funding over seven years could be as much as $201 million if all options are exercised in the NIAID contract.

CVD’s research is aimed at testing improved seasonal influenza vaccines and conducting controlled human influenza challenge studies for NIAID Collaborative Influenza Vaccine Innovation Center (CIVICs) program, which has the ultimate goal of developing a universal vaccine to protect against emerging influenza strains as well as improvements to current seasonal vaccines.

The seven-year contract will be led by CVD’s Dr. Neuzil, who is one of the world’s leading and preeminent research scientists and advocates in the area of vaccine development and policy. For more than four decades, CVD has worked domestically and internationally to develop, test and deploy vaccines to prevent and protect against a range of diseases, such as influenza, cholera, typhoid fever, malaria, shigellosis (bacillary dysentery), and other infectious diseases. CVD has also taken global leadership roles in vaccines to protect against emerging pathogens such as Zika and Ebola virus…



Ebola – DRC+
Public Health Emergency of International Concern (PHEIC)

Ebola Outbreak in DRC 60: 24 September 2019
Situation Update
In the past week, from 16 to 22 September, 39 new confirmed Ebola virus disease (EVD) cases, with an additional 22 deaths, have been reported from nine health zones in three affected provinces in the Democratic Republic of the Congo.

Pockets of insecurity in the affected areas, along with localised security incidents, continue to hinder response activities, including safe and dignified burials (SDB), vaccination, contact tracing and case reporting. For instance, a recent major security incident in Lwemba, within Mandima health zone is still preventing response activities in this area. Overall, these incidents underscore the need for continued and proactive engagement and sensitizing of local communities, especially in the high risk areas that may not currently be affected…

…The Democratic Republic of the Congo health authorities have endorsed the use of a second investigational Ebola vaccine with at-risk populations in areas that do not have active EVD transmission. Regular vaccination activities in EVD-affected areas will continue…

Implementation of ring vaccination protocol
As of 23 September 2019, 225 719 people at risk have consented to and received the rVSV-ZEBOV-GP Ebola vaccine. Of those, 55 801 are contacts and 154 689 contacts-of-contacts. The total number of vaccines includes 47 533 HCWs/FLWs.

The Democratic Republic of the Congo health authorities have endorsed the use of a second investigational Ebola vaccine, manufactured by Johnson & Johnson. This vaccine, which is administered as a two-dose course, 56 days apart, will be circulated in at-risk populations in areas that do not have active EVD transmission. Regular vaccination activities in EVD-affected areas will continue. The Merck/MSD vaccine will continue to be provided to all people at high risk of Ebola infection including those who have been in contact with a person confirmed to have Ebola, all contacts of contacts, and others determined to be at high risk of contracting Ebola…


Second Ebola vaccine to complement “ring vaccination” given green light in DRC
23 September 2019 Statement Geneva, Switzerland
The health authorities in the Democratic Republic of the Congo (DRC) have announced plans to introduce a second experimental Ebola vaccine, manufactured by Johnson & Johnson, from mid- October. This vaccine, which is given as a 2-dose course, 56 days apart, will be provided under approved protocols to targeted at-risk populations in areas that do not have active Ebola transmission as an additional tool to extend protection against the virus.

“The DRC authorities, in deciding to deploy the second experimental vaccine to extend protection against this deadly virus, have once again shown leadership and their determination to end this outbreak as soon as possible,” said WHO Director-General, Dr Tedros Adhanom Ghebreyesus.

The evaluation of the second Ebola vaccine will help ensure that we have potentially an additional tool to prevent the expansion of the outbreak and also a potential tool to protect populations before outbreaks hit areas at risk,” said Dr Matshidiso Moeti, WHO’s Regional Director for Africa.

The Johnson & Johnson vaccine will complement the current vaccine (rVSV-ZEBOV-GP, manufactured by Merck), which has proven highly effective and safe, and which has helped protect thousands of lives. The Merck vaccine will continue to be provided to all people at high risk of Ebola infection including those who have been in contact with a person confirmed to have Ebola, all contacts of contacts, and others determined to be at high risk of contracting Ebola. To date over 223,000 people have received this vaccination during the current outbreak.

In May 2019, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) reviewed use of vaccines in the ongoing Ebola outbreak and issued recommendations. These included adjusting the dose of the Merck vaccine, evaluating a second vaccine under appropriate protocols, changing strategies when insecurity makes it difficult to reach people – such as providing pop-up vaccination stations — and increasing the number of people vaccinated within communities with ongoing transmission, sometimes vaccinating whole villages.

“In everything we do, we are driven by science,” Dr Tedros said. “The advice we were given by SAGE in May has been applied, always taking into account community needs and preferences, as we know this will make the approach more effective. The changes made have saved thousands of lives in this outbreak.”

New therapeutics and better use of treatment protocols have also saved many lives. “To date, 973 people have been successfully treated and released from Ebola treatment centres, and we expect that the 1000th survivor will return to his or her community in the coming weeks,” Dr Moeti said.

Innovative vaccine strategies
The introduction of the second experimental vaccine is in line with the SAGE recommendations as are a number of other innovations.

The main vaccination strategy used with the rVSV-ZEBOV-GP vaccine is a ‘ring strategy’ where all people who have come into contact with someone with a confirmed case of Ebola are given the vaccine. Where people are stigmatized or feel under threat protected, temporary ‘pop-up’, vaccination sites are set up, often at health posts, rather than near the homes of individuals infected with Ebola. This allows people to come for vaccination at a safe, more anonymous site, but also increases protection for vaccinators in areas where there is ongoing conflict and insecurity.

Another approach being used to offer vaccination for people at high risk of contracting Ebola is ‘targeted geographic vaccination’. This strategy involves vaccinating everyone in the neighbourhood, or village, rather than vaccinating only the known contacts and contacts of contacts. Targeted geographic vaccination was used successfully when the outbreak spread to Chowe in South Kivu. Over 90 percent of people who are offered vaccination accept it. Since the start of the outbreak WHO and partners have worked to recruit and train Congolese nationals from within Ebola-affected communities as vaccinators to increase community acceptance and also transfer skills to the region. Now, the majority of ring vaccination team members are trained healthcare workers, doctors and medical students from affected communities who speak local languages and understand community concerns.

There are enough vaccine doses on the ground to meet the current needs, with WHO logisticians ensuring a minimum supply of 10,000 doses at all times, and overall supplies of the vaccine are being constantly monitored. Considering the current number of cases being reported and the doses required to vaccinate around each case, the doses available of the rVSV-ZEBOV-GP vaccine are considered sufficient. Merck has provided WHO with 245,000 doses for DRC and neighbouring countries and built a stockpile of 190,000 doses that are ready to send to DRC. Merck also aims to release 650,000 doses over the next six to 18 months under its replenishment strategy. Under the current SAGE recommendations this means that there are 390,000 doses currently and additional 1.3 million doses will be available.

“The Merck vaccine is highly efficacious, and we’ll soon have a second vaccine to increase the number of those being protected against the virus”, said Dr Tedros. “But vaccine and therapeutics are only some of the tools — the key to ending the outbreak is community ownership. With the communities fully engaged, and with all partners stepping up and rallying behind our common goal, we can and will end this outbreak.”


Médecins Sans Frontières (MSF) – DRC Ebola outbreaks
Independent Ebola vaccination committee is needed to overcome lack of WHO transparency
Press Release 23 Sep 2019
:: The current Ebola outbreak has a mortality rate comparable to the West Africa outbreak, despite new treatments and vaccines being available.
:: Not enough eligible people have been vaccinated, one reason for which is WHO’s strict limits on the number of doses used in the field.
:: We call for the establishment of an international, independent committee to transparently manage Ebola vaccine stocks and their use.

…WHO tightly controlling vaccine supplies and access
MSF’s efforts to expand access to vaccination, in collaboration with the Ministry of Health and according to the recommendations of the Strategic Advisory Group of Experts (SAGE) in May 2019, have been frustrated by the tight controls on supply and eligibility criteria imposed by WHO. MSF vaccination teams have often been forced to remain on standby in North Kivu, waiting to receive a handful of doses reserved to people on a pre-defined list.

“Time is of the essence in an outbreak: medical teams should be able to rapidly provide treatments or vaccines based on what they see on the ground,” says [Dr Natalie Roberts, MSF Emergency Coordinator. “If a mother has been caring for her sick child who is then diagnosed with Ebola, not only do we want to diagnose and treat the child, but also we also want to provide the mother with post-exposure prophylaxis that could potentially prevent her from developing the disease, and vaccinate her whole community so that if she does get sick, they will have already developed immunity.”

“But our capacity to carry out real-time assessments and react accordingly is severely undermined by a rigid system which is hard to comprehend,” Dr Roberts says. “It’s like giving firefighters a bucket of water to put out a fire, but only allowing them to use one cup of water a day. Every day we see known contacts of confirmed Ebola patients who have not received their dose despite being eligible for vaccination.”

Such restrictions seem unjustified: rVSV-ZEBOV vaccine has demonstrated a good safety profile and a high level of protection against the virus in a Phase-3 clinical trial in Guinea in 2015. In the absence of regulatory approval, the Congolese Ministry of Health and WHO allowed the vaccine to be used under an ‘Expanded Access’ framework. Manufacturer Merck recently stated that in addition to the 245,000 doses already delivered to WHO, they are ready to ship another 190,000 doses if required, and that 650,000 additional doses will be available over the next six to 18 months.

Independent coordination committee needed to manage vaccines
“To allow for the best possible use of experimental tools in an outbreak context, transparency is key,” continues Dr Roberts. “How can we support the Congolese authorities in using these tools, how can we expect the Congolese people to trust a system that is not even transparent to front-line health workers like MSF?”

Médecins Sans Frontières calls for the urgent creation of an independent, international coordination committee, based on the model of the International Coordination Group created in 1997 composed of MSF, the International Federation of Red Cross, UNICEF and WHO, which proved successful in managing massive meningitis, cholera and yellow fever outbreaks with limited vaccine supplies. The committee would bring partners together to improve coordination on vaccination, increase transparency in stock management, share data, foster an open dialogue with the manufacturers and ultimately ensure that the vaccine is provided to all those most at risk of being exposed to the virus.


Public Health Emergency of International Concern (PHEIC)

Polio this week as of 25 September 2019
:: The Global Polio Eradication Initiative and the Pakistan Polio Programme are looking for innovative ways to help quickly detect, control and/or respond to the spread of anti-vaccination propaganda on social media in an urban population. For more information on how to join this collective effort  please click here.
:: Look through the lives of polio vaccinators in Somaliland as they reach out to vaccinate nomadic communities.

Summary of new viruses this week:
:: Afghanistan — one wild poliovirus type 1 (WPV1)- positive environmental sample;
:: Pakistan — four WPV1 cases and seven WPV1-positive environmental samples;
:: Nigeria — one circulating vaccine-derived poliovirus type 2 (cVDPV2)- positive case;
:: Angola — four cVDPV2 cases;
:: Myanmar — two cVDPV1 cases.


Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies [to 28 Sep 2019]

Democratic Republic of the Congo
:: Ebola Outbreak in DRC 60: 24 September 2019
:: WHO and partners launch emergency vaccination campaign to help contain world’s largest measles outbreak 25 September 2019 [link not operative at inquiry]

Mozambique floods
:: Dr Joaquim da Silva Physician and post-emergency WHO operations officer in Sofala province
25 September 2019

South Sudan
:: South Sudan validates and costs its National Action Plan for Health Security 26 Sep 2019
With support from the World Health Organization (WHO), South Sudan has developed and costed a National Action Plan for Health Security, which is a comprehensive, multisectoral blueprint to strengthen the country’s core capabilities to manage health risks (as well as save lives and avoid interference to international trade and travel) during emergency situations, as required by the legally binding International Health Regulations (2005).

Syrian Arab Republic
:: WHO statement on mortality in Al Hol camp in Syrian Arab Republic 22 September 2019
:: Greater support needed to ensure accessible quality health services for a quarter of a million Syrian refugees in Iraq 22 September 2019

Nigeria – No new digest announcements identified
Somalia – No new digest announcements identified
Yemen – No new digest announcements identified


WHO Grade 2 Emergencies [to 28 Sep 2019]

Measles in Europe
:: WHO urges investments to stop measles transmission in Europe 24-09-2019
The first-ever WHO Strategic Response Plan (SRP) for a measles emergency was launched today to ensure financial commitment to stop the spread of this highly contagious and serious disease in the WHO European Region.
Over 120,000 measles cases were reported between August 2018 and July 2019, which is more than the total number for a 12-month period reported in the Region in over a decade. Of the Region’s 53 countries, 48 reported cases in this period.
As measles continues to circulate in the Region, a stronger response by the international community is needed. In May this year, WHO classified measles outbreaks across the Region as a Grade 2 emergency. The newly launched SRP provides a resource mobilization tool to accelerate tailored interventions in measles-affected and at-risk countries, where investments will have the greatest possible impact…

:: Critical WHO supplies arrive in Sudan to manage cholera outbreak 25 September 2019
[Editor’s Note: No mention of OCV in announcement]

Afghanistan – No new digest announcements identified
Angola – No new digest announcements identified
Burkina Faso [in French] – No new digest announcements identified
Burundi – No new digest announcements identified
Cameroon – No new digest announcements identified
Central African Republic – No new digest announcements identified
Ethiopia – No new digest announcements identified
HIV in Pakistan – No new digest announcements identified
Iran floods 2019 – No new digest announcements identified
Iraq – No new digest announcements identified
Libya – No new digest announcements identified
Malawi floods – No new digest announcements identified
MERS-CoV – No new digest announcements identified
Myanmar – No new digest announcements identified
Niger No new digest announcements identified
occupied Palestinian territory – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified


WHO Grade 1 Emergencies [to 28 Sep 2019]

:: Sense of relief as families embrace malaria vaccine roll out in Kenya 24 September 2019

Chad – No new digest announcements identified
Djibouti – No new digest announcements identified
Mali – No new digest announcements identified
Namibia – viral hepatitis – No new digest announcements identified
Tanzania – No new digest announcements identified


UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: Syria: Rukban Humanitarian Update (As of 25 September 2019)

Yemen – No new digest announcements identified


UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Editor’s Note:
Ebola in the DRC has bene added as a OCHA “Corporate Emergency” this week:
CYCLONE IDAI and Kenneth – No new digest announcements identified
EBOLA OUTBREAK IN THE DRC – No new digest announcements identified